Give President Trump credit for acting on his promise to bring down prices for prescription drugs. But one policy idea his administration has proposed needs a second look.
The Department of Health and Human Services has proposed a rule that would end rebates that drug companies pay to Part D and Medicaid-managed organizations for the prescription drug equivalent of preferential shelf placement and instead require savings from any such rebates be passed along to consumers.
